Clinical trials: Mammographic Density Reduction

Mammographic Breast Density

Trial of 4-Hydroxytamoxifen (4-OHT) Gel in Women Aimed at Reducing Dense Breast Tissue

• Terminated
• Age: 35 to 75 years
• Phase 3
• Results posted

A study to determine the efficacy of 8 mg/day (4 mg/breast) of BHR-700 gel compared to placebo for reducing breast tissue density in women identified as having dense breast tissue upon analysis of screening mammography.

Trial name

4WARD (NCT03199963)

Testing

4-OH tamoxifen

Where

19 sites in United States, Germany and 1 more

Volunteers

223 people

Sponsor

BHR Pharma, LLC